ArticleDiscover oncology2026
Ubiquitin-specific protease 19 promotes M2 macrophage polarization and ovarian cancer progression via NLRP3 suppression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- POU2F2 as a dual oncogenic and immunomodulatory driver in kidney renal clear cell carcinoma.Cell adhesion & migration · 2026Article
- LncRNA GAS5 inhibits the remodeling of the tumor microenvironment by binding to miR-93-5p, thereby suppressing the development of osteosarcoma.Journal of orthopaedic surgery and research · 2026Article
- The NLRP3 inflammasome in gynecological cancers: a double-edged sword shaping the immune microenvironment and immunotherapy response.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpithelial ovarian cancer (EOC) is an aggressive malignancy marked by late diagnosis, recurrence, and treatment resistance. Tumor-associated macrophages (TAMs) play pivotal role in EOC progression, particularly through polarization into the pro-tumorigenic M2 phenotype. Ubiquitin-specific protease 19 (USP19), a deubiquitinase implicated in oncogenesis, regulates immune responses via the NLRP3 inflammasome. However, its role in EOC remains unclear. This study aims to investigate the role of USP19 in EOC progression and TAM polarization.
methodsThe expression levels of USP19 and its subcellular localization were evaluated in human EOC cell lines C13K, SW626, and A2780 using RT-qPCR, Western blot, and immunofluorescence. USP19 knockdown models were established in A2780 cells to assess the effects of USP19 on cell proliferation, migration, invasion, and macrophage polarization in co-culture systems. Cytokine levels, macrophage markers, and epithelial-mesenchymal transition (EMT) marker expression were analyzed using ELISA, flow cytometry, and Western blot, respectively.
resultsUSP19 was significantly upregulated in EOC cells and predominantly localized in the cytoplasm, co-localizing with NLRP3. Knockdown of USP19 inhibited proliferation, migration, invasion, and EMT marker expression in A2780 cells. Additionally, USP19 suppression promoted TAM polarization towards the pro-inflammatory M1 phenotype by enhancing the expression of IL-12 and CXCL10 while reducing M2 markers such as CD206. Dual-conditioned medium from USP19-deficient cells significantly mitigated the malignant phenotypes of EOC cells, indicating a disrupted TAM-mediated feedback loop.
conclusionUSP19 drives EOC progression by promoting M2 macrophage polarization and suppressing NLRP3-mediated inflammatory responses. Targeting USP19 may represent a novel therapeutic strategy to modulate the tumor immune microenvironment and inhibit EOC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.